# Roy S. Herbst
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/roy-s-herbst/
## Facts
| Field | Value |
| --- | --- |
| Citations | 94,314 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 135 |
| i10-index | 488 |
| Last Known Institution | Yale Cancer Center |
| OpenAlex ID | https://openalex.org/A5008593691 |
| ORCID iD | https://orcid.org/0000-0003-2535-5847 |
| Works | 1,339 |
## Researcher papers
Showing 12 of 21.
- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-gefitinib-an-inhibitor-of-the-epidermal-growth-factor-receptor/)
- [Lung Cancer](https://scholariq.org/papers/lung-cancer/)
- [Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/tribute-a-phase-iii-trial-of-erlotinib-hydrochloride-osi-774-combined-with/)
- [An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance](https://scholariq.org/papers/an-epithelial-mesenchymal-transition-gene-signature-predicts-resistance-to-egfr/)
- [Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities](https://scholariq.org/papers/co-occurring-genomic-alterations-define-major-subsets-of-i-kras-i-mutant-lung/)
- [The BATTLE Trial: Personalizing Therapy for Lung Cancer](https://scholariq.org/papers/the-battle-trial-personalizing-therapy-for-lung-cancer/)
- [Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/quantitative-assessment-of-the-heterogeneity-of-pd-l1-expression-in-non-small/)
- [Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer](https://scholariq.org/papers/impaired-hla-class-i-antigen-processing-and-presentation-as-a-mechanism-of/)
- [Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC](https://scholariq.org/papers/liquid-biopsy-for-advanced-non-small-cell-lung-cancer-nsclc-a-statement-paper/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
## Researcher university
- [Yale Cancer Center](https://scholariq.org/institutions/yale-cancer-center/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.